Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis
Authors:
Open Access
- 27 December 2018
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 49 (2) , 140-146
Abstract
Summary: Background: Proton pump inhibitors (PPIs) are widely used to treat gastro‐oesophageal reflux disease (GORD). However, the onset of action is considered slow and PPIs cannot completely block acid secretion at night. A new potassium‐competitive acid blocker (P‐CAB) can rapidly block acid secretion. However, whether this P‐CAB can relieve GORD symptoms quickly and adequately soon after starting treatment is unknown.Aim: To determine how rapidly vonoprazan and lansoprazole provide heartburn relief.Methods: Patients (n = 32) with endoscopically confirmed erosive oesophagitis who experienced heartburn at least once a week were randomised in a double‐blind manner to receive either daily vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days. Day time and night time heartburn were assessed daily throughout the study using a five‐point Likert scale. The primary endpoint was the first day of complete day and night heartburn relief for at least seven consecutive days. The ethics committees of the participating institutions approved the study protocol.Results: Heartburn was relieved sooner with vonoprazan than with lansoprazole (P < 0.05, log‐rank test). Heartburn was completely relieved in 31.3% and 12.5% of patients on day 1 with vonoprazan and lansoprazole, respectively. Significantly more patients achieved complete nocturnal heartburn relief with vonoprazan than lansoprazole (P < 0.01). Both regimens were well tolerated.Conclusions: Complete sustained heartburn relief was achieved sooner with vonoprazan than with lansoprazole during the first week of therapy. (UMIN000018776)Keywords
Funding Information
- Hyogo College of Medicine
This publication has 46 references indexed in Scilit:
- Gastroesophageal reflux disease and sleep disturbancesJournal of Gastroenterology, 2012
- A Study Comparing the Antisecretory Effect of TAK-438, a Novel Potassium-Competitive Acid Blocker, with Lansoprazole in AnimalsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Novel Approaches to Inhibition of Gastric Acid SecretionCurrent Gastroenterology Reports, 2010
- 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related DiseasesThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self‐treating subjectsAlimentary Pharmacology & Therapeutics, 2009
- Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatmentScandinavian Journal of Gastroenterology, 2006
- Development and evaluation of FSSG: frequency scale for the symptoms of GERDJournal of Gastroenterology, 2004
- Intragastric acid suppression and pharmacokinetics of twice‐daily esomeprazole: a randomized, three‐way crossover studyAlimentary Pharmacology & Therapeutics, 2004
- Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazoleAlimentary Pharmacology & Therapeutics, 1996
- Comparison of Once-Daily Intravenous and Oral Omeprazole on Pentagastrin-Stimulated Acid Secretion in Duodenal Ulcer PatientsDigestion, 1992